Does Adjuvant Therapy Benefit High-Risk Liver Cancer Patients? Insights from IMbrave050

Richard S. Finn, MD, and Adam Yopp, MD, explore the evolving role of adjuvant therapy in hepatocellular carcinoma following surgical resection. They discuss key findings from the IMbrave050 study evaluating atezolizumab and bevacizumab, highlighting the initial recurrence-free survival benefit observed at interim analysis and the impact of longer follow-up on those results. The conversation addresses challenges with maintaining long-term benefits, the influence of crossover design on overall survival outcomes, and potential signals of benefit in high-risk patient subgroups.